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Abstract 
Objectives: Liver metastases appear in 20–30% of patients diagnosed with non‑small cell lung cancer (NSCLC) and 
represent a poor prognosis feature of NSCLC and a possibly more treatment‑resistant condition. Potential clinical out‑
come differences in NSCLC patients with liver metastases harboring molecular alterations in EGFR, KRAS and EML4‑ALK 
genes are still to be determined. This study aims to evaluate the incidence of liver metastasis in a single population 
and look for potential correlations between EGFR mutations, liver infiltration and clinical outcomes.
Methods: A total of 236 consecutive stage IV NSCLC patients treated at the Clínica Universidad de Navarra were 
analyzed.
Results: At onset, liver metastases were present in 16.9% of patients conferring them a shorter overall survival 
(OS) compared to those with different metastatic locations excluding liver infiltration (10 vs. 21 months; p = 0.001). 
Patients with EGFR wild‑type tumors receiving standard chemotherapy and showing no liver involvement presented a 
superior median OS compared to those with liver metastases (23 vs. 13 months; p = 0.001). Conversely, patients with 
EGFR‑mutated tumors treated with EGFR tyrosin‑kinase inhibitors (TKI’s) presented no significant differences in OS 
regardless of liver involvement (median OS not reached vs. 25 months; p = 0.81).
Conclusion: Overall, liver metastases at onset negatively impact OS of NSCLC patients. EGFR TKIs however, may 
reverse the effects of an initial negative prognosis of liver metastasis in first‑line treatment of EGFR mutated NSCLC 
patients.
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Background
More than 1,820,000 new cases of lung cancer were diag-
nosed in 2012 worldwide, leading to more than 1,500,000 
annual deaths [1]. More than 50% of the patients diag-
nosed with non-small cell lung cancer (NSCLC) are 
expected to present advanced disease (stage III and IV) 
at onset associated with an overall survival (OS) barely 
exceeding 10–12 months from treatment initiation [2].
Although the most common site of metastases in stage 
IV NSCLC subjects is still to be determined [3], the 
organs most commonly colonized by primary non-small 
cell lung tumors are brain, bone, lung, adrenal glands, 
and liver.
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It has been also postulated that those different meta-
static locations may confer a diverse prognosis [3] and/or 
likelihood of disease response to the treatment [4].
In light of recent research on biological targets and 
the progressive development of new tailored therapies 
in NSCLC patients, there is a need to reassess the prog-
nostic/predictive implications of different metastatic 
locations. Additionally, the recent development of new 
local (mainly ionizing radiation-based) therapies has con-
tributed to the improved survival of patients with brain 
metastases [5], a metastatic location that has been tradi-
tionally known to entail a particularly poor prognosis [6].
Liver involvement appears in a range of 20–30% of 
NSCLC patients during the disease course conferring a 
significantly poorer prognosis to NSCLC at any stage 
of the disease since no local consolidation therapies are 
commonly used on a routine clinical practice [7].
Nevertheless, the impact different tumor histology and 
molecular characteristics may have on the spread of the 
disease to the liver is unknown. The current study aims 
to analyze the last consecutive stage IV NSCLC patients 
treated at our institution, paying special attention to the 
prevalence and outcome implications of liver metastases 
and correlated to the EGFR mutation status.
Patients and methods
Patients’ clinical and molecular characteristics
This study was designed as a retrospective analysis 
of a single cohort, reviewing and including the medi-
cal records of 236 histologically-confirmed stage IV 
NSCLC consecutive patients starting systemic antineo-
plastic treatment from 2006 to 2014. All patients signed 
informed consent before undergoing any diagnostic pro-
cedure leading to the obtention of tumor samples, or fol-
low up imaging studies that required so. The only patient 
selection criterion applied was the availability of basic 
clinical information about the tumor histology confir-
mation, treatment administrated and at least 6  months 
follow-up.
All available characteristics including tumor histology 
and molecular features, the number of metastatic loca-
tions and organs affected were collected from patients’ 
medical charts. Overall, 236 consecutive NSCLC 
patients diagnosed with metastatic disease at the time of 
presentation were reviewed and included in the analysis. 
Main patients’ characteristics including their tumors’ 
histological patterns are summarized in Additional file 1: 
Table S1.
The molecular analysis performed on tumor samples 
included the assessment of Epidermal Growth Factor 
Receptor (EGFR) mutations in exons 18, 19, 20 and 21 
and the assessment of Kristen Rat Sarcoma (KRAS) gene 
mutations in codons 12 and 13.
In brief, after the sample was fixed in alcohol and 
stained by Papanicolau stain, DNA was extracted and 
amplified via a PCR technique that uses EGFR gene exons 
18, 19, 20 and 21 specific primers. ABI PRISM® 310 
Genetic Analyzer equipment was used for the analysis of 
the sequencing reactions with both forward and reverse 
primers. Following the same process used for EGFR anal-
ysis, PCR was used for DNA amplification, using KRAS 
gene exon 2 primer. ABI PRISM® 310 Genetic Analyzer 
equipment was also used for the analysis of the sequenc-
ing reactions with both forward and reverse primers.
Smoking habits were also collected in accordance with 
the National Health Interview Survey (NHIS) for stand-
ard smoking definitions [8].
The protocol was approved by the Research Ethics 
Committee of the University of Navarra.
Outcome measures
Patients were regularly followed during treatment for 
clinical and radiological response assessment. Comput-
erized tomography (CT) scans were performed every 
6 weeks as per institutional standard protocol.
The best radiological response to treatment was 
reviewed according to Response Evaluation Criteria In 
Solid Tumors (RECIST v1.1).
OS was calculated and compared between different 
groups. OS was calculated from the date of diagnosis to 
the date of death, lost to follow up, or last contact with 
the patient.
Statistical analysis
To analyze the quantitative variables within the study 
population, a comparison was made using a Shapiro–
Wilk test between the distribution of patients showing 
liver metastasis and those without liver involvement. 
Depending on the results of this test, either an unpaired 
2-tailed Student’s t test or Mann Whitney test for para-
metric and non-parametric distribution, were used. A 
Chi2 test was also used to analyze the qualitative vari-
ables. OS was analyzed using the Kaplan–Meier (KM) 
method. A Log rank test or Taron Ware test was used to 
evaluate the differences among survival curves according 
to the curves’ distribution. We performed a multivari-
ate regression model using Cox Regression method. A 
p value of <0.05 was considered statistically significant. 
Statistical analyses were conducted with the IBM SPPS 
statistical software package (v15.0 SPSS Inc. Chicago, IL).
Results
Molecular analysis
An EGFR mutational study was available in 73.7% of the 
patients (n = 174). KRAS was also studied in 44% of the 
population (n = 104).
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Molecular findings are reflected in Additional file  2: 
Table  S2, including the specification of the mutations 
detected. EGFR mutational status according to the pat-
tern of metastasis at onset and during disease curse is 
summarized in Additional file 3: Table S3.
Pattern of metastases
The most prevalent site of metastasis at onset cor-
responded to bone (94/236; 39.8%) followed by brain 
(75/236; 31.8%), adrenal glands (44/236; 18.6%), liver 
(40/236; 16.9%), bilateral lung lesions (25/236; 10.6%), 
pleural implants (19/236; 8.1%) and skin metastases 
(10/236; 4.2%). The final metastatic localization devel-
oped during treatment and follow-up was as follows, 
bone (49.2%), brain (42.8%), liver (39%), adrenal glands 
(28.4%), bilateral lung involvement (18.2%), pleural 
implants (11%) and skin metastases (7.2%).
Liver involvement implications on patients’ epidemiology
We divided our population in two groups, whether liver 
involvement was present or not. Both groups of patients 
were compared in order to detect potentially different 
clinical characteristics among those patients harboring 
liver metastases and those with NSCLC who had metas-
tasized to different organs other than the liver. No sig-
nificant differences in gender, age, ECOG performance 
status (PS) or smoking history were found to be corre-
lated to liver involvement (Chi squared test, T test and 
Mann Witney test were used for categorical and quanti-
tative variables; p =  0.62, p =  0.05; p =  0.35; p =  0.23, 
respectively). The total number of chemotherapy lines 
received was slightly higher among subjects without liver 
dissemination compared to those showing liver involve-
ment (mean 2.41, 95% CI 2.1–2.7 vs. 1.84, CI 1.6–2.03, 
respectively; T test result: p = 0.001).
A higher proportion of tumors with adenocarcinoma 
histology among patients who were not exhibiting liver 
metastasis was observed (83.3 vs. 52.2%; Chi square test: 
p  =  0.001), whereas large-cell carcinoma seemed to be 
significantly more frequent among patients with liver 
involvement (16.3 vs. 6.25%; Chi square test: p =  0.01). 
Patients with squamous cell histology tumors were 
slightly higher prevalent in the group with liver metasta-
ses compared to those without liver spread disease (16.3 
vs. 9.7%; Chi square test: p = 0.09) although no statistical 
differences were observed.
Regardless of liver involvement, EGFR and KRAS status 
were equally balanced among patients, (Chi square test: 
p = 0.83 and p = 0.78, respectively).
As expected, the use of first-line EGFR TKIs was sig-
nificantly related to the EGFR mutation status. In fact, 
while the first-line EGFR TKIs use among EGFR mutated 
patients was 56.7% (17/30), it was 2.1% (3/144) among 
EGFR wild type patients (Chi square test: p  =  0.001). 
The use of EGFR TKIs as a second or subsequent line in 
patients with EGFR mutated tumors was 42.8% (12/30) 
compared to 19.8% (26/144) in subjects with EGFR wild 
type tumors (Chi square test: p = 0.008). However, their 
use did no differ from patients without liver metastases 
compared to those with secondary liver involvement 
(12.6 vs. 9.1%; Chi square test: p = 0.49).
Survival impact
As expected, a significant OS benefit was observed for 
patients with stage IV NSCLC showing no liver involve-
ment at onset when compared to those exhibiting liver 
infiltration at the time of stage IV diagnosis [KM survival: 
21  months (95% CI 16.9–25.1) vs. 10  months (95% CI 
2.8–17.2); p = 0.001], (Fig. 1a). When taken into account 
the presence of LM at any time-point during the entire 
disease process, we found a shorter OS [14 months (95% 
CI 11.6–16.4)] in patients with liver disease, when com-
pared to those patients in which liver was never affected 
[24 months (95% CI 18.6–29.3), p = 0.038], (Fig. 1b).
Additionally, a subanalysis was performed in order to 
study the impact of EGFR mutation status and the treat-
ment with EGFR TKIs on the OS according to the pres-
ence or absence of liver involvement. Among patients 
with liver involvement, those with EGFR mutated tumors 
experienced a significantly superior OS compared to 
subjects with EGFR wild-type neoplasms [median OS 
not reached (95% CI not reached (N.R.)] vs. 13 months 
(95% CI 10.2–15.7), respectively; (HR = 0.06; p = 0.001) 
(Fig.  2a). Similarly, patients without liver involvement 
and EGFR mutated tumors showed a superior OS com-
pared to those with EGFR wild type NSCLC [39 months 
(95% CI 20.2–57.8) vs. 23 months (95% CI 17.2–28.8); 
p = 0.047], (Fig. 2b).
Subsequently, we analyzed the impact on the OS of 
the EGFR TKIs treatment in those patients with EFGR 
mutant tumors receiving first-line targeted therapy, 
according to the presence or absence of secondary liver 
involvement. On the one hand, when the OS analysis 
was restricted to EGFR wild-type NSCLC patients who 
received standard first-line chemotherapy, a clear benefit 
in OS was observed in favor of individuals without liver 
involvement compared to those patients with liver dis-
ease [23 months (95% CI 13.1–32.9) vs. 13 months (95% 
CI 8.1–17.9), respectively; p = 0.001]. In fact, those sub-
jects showing liver involvement presented a 117% higher 
risk of death than patients with no liver involvement 
(HR = 2.17), (Fig. 3a). Interestingly enough and in con-
trast with our previous results, liver involvement lost its 
prognostic impact among patients with EGFR mutated 
tumors receiving first-line EGFR TKIs therapy. Thus, 
a non-statistically significant benefit in OS in subjects 
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without liver metastases compared to those with liver 
involvement was observed [median OS not reached (95% 
CI N.R.) vs. 25 months (95% CI 15.8–34.1); p  =  0.81], 
(Fig. 3b).
Finally, a Cox regression model was performed for 
assessing prognostic factors in terms of OS for the 
population in which EGFR mutation status had been 
studied (n  =  174). In the univariate analysis, nodal 
involvement (HR  =  1.29, p  =  0.02), EGFR mutation 
(HR = 0.31, p = 0.01), use of EGFR TKIs after progres-
sion (HR = 0.4, p = 0.03), liver metastases at onset local-
ized in liver (HR =  2.25, p =  0.001), bone (HR =  2.13, 
p  =  0.001), adrenal glands (HR  =  1.75, p  =  0.03) and 
skin (HR  =  4.67, p  =  0.03) constituted factors related 
to OS. Also, the appearance of metastases in the liver 
(HR  =  1.48, p  =  0.04) and in the bone (HR  =  1.93, 
p  =  0.01) during the disease curse were also related 
to a poorer outcome  (Additional file  4: Table  S4). After 
Fig. 1 OS depending on the presence of LM at onset or during disease curse. a At onset, LM presence seems to be a poor prognosis factor detect‑
ing an OS of 10 months when LM are present (n = 40) compared to 21 months when no liver metastases are diagnosed at the moment of stage 
IV NSCLC diagnosis (n = 196). b A better overall survival is achieved in stage IV NSCLC patients who never present liver involvement (n = 144) 
compared to those patients in whom LM are present during the course of the disease (n = 86).
Fig. 2 OS depending on the EGFR status stratified by the presence of LM. a A subanalysis was performed selecting those patients with liver involve‑
ment. We observed a significant difference between those patients harboring EGFR mutations (n = 9) compared to those showing wild‑type EGFR 
(n = 46). b When selecting patients with no liver involvement, we also observed a better outcome for those harboring EGFR mutation (n = 21) 
compared to those with EGFR wild type NSCLC (n = 98).
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introducing these variables in a multivariate analysis, 
metastatic localization, including liver involvement, lost 
its prognostic value when adjusted by EGFR mutations 
and TKIs use. In fact, the presence of EGFR mutations 
(HR = 0.24, p = 0.001) and the use of EGFR TKIs after 
progression to chemotherapy (HR = 0.44, p = 0.03), were 
independently related to a better survival in stage IV 
NSCLC, (Additional file 5: Tables S5).
Discussion
It is known that the development of liver metastasis con-
fers a poor prognosis to NSCLC patients, since no local 
treatments are still widely used to specifically target liver 
involvement in unselected patients [9, 10].
The first interesting finding in our study is that 
although liver involvement was present in only 16.3% of 
the patients at onset, the liver became the third most fre-
quent site of metastasis during the course of the disease, 
closely following bone and brain locations and in accord-
ance with previous reports [3].
More interestingly, we confirm that subjects with liver 
infiltration are among those who significantly obtain 
less clinical benefit from chemotherapy administra-
tion. Therefore, liver involvement seems to be a poor 
prognostic feature with a significantly reduced survival 
expectation compared to other patients with metastatic 
disease who never develop liver metastasis, as previously 
reported [4]. Moreover, brain metastasis seemed to pro-
vide even a better prognosis to the rest of the patients 
compared to liver involvement, most probably because in 
our clinical cohort all patients with brain metastasis were 
locally treated with either whole brain irradiation or ste-
reotactic body radiation therapy.
Furthermore, we found that the tumor genotype 
seemed to correlate with the pattern of metastasis 
observed. A previous study by Doebele et al. [11] showed 
that NSCLC patients with EGFR mutations were signifi-
cantly predisposed to liver metastasis compared to the 
triple negative cohort. In contrast, in our series EGFR 
mutant patients did not seem to be more prone to devel-
oping liver metastasis compared to EGFR wild type 
patients. Potential different characteristics in our popula-
tion, in which for example ALK rearrangement was not 
studied, may explain the differences detected compared 
to the study by Doebele el al.
It has been extensively demonstrated that NSCLC 
patients with EGFR mutated tumors clinically ben-
efit from receiving a first-line treatment with an EGFR 
TKI, such as erlotinib [12], gefitinib [13] or afatinib [14] 
reaching a median progression free survival of around 
10 months and an OS superior to 22 months in most of 
the published clinical trials [13–15]. However, in those 
clinical trials no specific subanalysis showing the clini-
cal outcome of patients with liver metastasis has been 
reported.
Therefore, in the present study we aimed to investigate 
whether the molecular tumor subtype influenced the 
clinical outcome of NSCLC patients with liver involve-
ment, and more importantly, by the targeted therapy 
received.
Fig. 3 OS in patients with LM depending on EGFR status. a EGFR wild‑type NSCLC patients who received standard first‑line chemotherapy pre‑
sented a clear benefit in terms of OS when liver was not involved (n = 96) compared to those patients with LM (n = 45). b No differences were 
observed in EGFR mutated population receiving first line TKI in terms of OS when comparing patients with no LM (n = 13) with patients with liver 
involvement (n = 4).
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For the first time in the literature, we found that the 
OS of subjects with liver involvement does not signifi-
cantly differ from that of those with different metastatic 
locations other than the liver, when considering the 
subpopulation of patients with EGFR-mutated tumors 
treated with a first-line EGFR TKI. In contrast to what it 
is observed in EGFR wild-type patients receiving stand-
ard chemotherapy. This finding would suggest that the 
sensitivity to EGFR targeted therapies in EGFR mutant 
NSCLC patients is not compromised in any way by the 
specific location of the metastasis. On the other hand, 
this observation could be well explained by the fact that 
chemotherapy induces lower response rates and requires 
more time to produce a clinically relevant response in 
EGFR wild type patients compared to EGFR TKIs in 
subjects with mutated tumors. In that case, liver infil-
tration would cause a faster clinical deterioration and 
a rapid worsening of the patient’s performance status 
with a subsequent earlier discontinuation of active treat-
ment. In fact, the total number of chemotherapy lines 
received was significantly higher among subjects with-
out liver dissemination compared to those showing liver 
involvement. In contrast, the early clinical and radio-
logical response commonly seen among NSCLC patients 
with tumors harboring EGFR activating mutations who 
receive EGFR TKIs would contribute to a rapid improve-
ment in the patient’s clinical condition and PS, allowing 
those patients to continue treatment for longer periods 
benefiting more extensively from therapy.
Some early clinical data have shown that EFGR TKIs 
gefitinib and erlotinib are mainly metabolized in the liver. 
Liver dysfunction may contribute to an overexposure to 
the drug [16–18]. Therefore, it could be hypothesized 
that the overexposure to the drug may lead to a poten-
tially higher efficacy of EGFR TKIs among patients with 
liver dysfunction resulting from liver metastases.
The retrospective nature of this study and some lacking 
data are potential limitations for the present study. More 
specifically, in the subgroup analysis of EGFR mutated 
tumors in patients receiving first-line EGFR TKIs with 
regards to liver involvement. Nevertheless, the total num-
ber of patients analyzed and the results obtained therein 
warrant a thorough analysis of previous prospective trials 
in order to identify potential differences in survival that 
may result from the metastatic locations and the molecu-
lar profile of the tumors.
Conclusions
Subjects with NSCLC and liver infiltration present an over-
all poorer prognosis obtaining less clinical benefit from 
chemotherapy administration. Conversely, the OS of sub-
jects with liver involvement did not significantly differ from 
those with other metastatic locations when considering the 
subpopulation of patients with EGFR mutations harboring 
tumors treated with a first-line EGFR TKI.
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